0 -thio analogue (5h) of IB-MECA showed extremely high binding affinity (K i = 0.25 nM) at the human A 3 AR and was more potent than IB-MECA (K i = 1.4 nM). Bulky substituents at the 5 0 -uronamide position, such as cyclohexyl and 2-methylbenzyl, in this series of 2-H nucleoside derivatives were tolerated in A 3 AR binding, although small alkyl analogues were more potent.
Introduction
The A 3 adenosine receptor (AR), which belongs to the family of G-protein-coupled receptors (GPCRs), is known to be involved in cell signaling by modulating the levels of cAMP, inositol triphosphate (IP 3 ), and diacylglycerol (DAG) through binding of the endogenous chemical messenger, adenosine.
1 Thus, the A 3 AR has been regarded as good therapeutic target for the treatment of several diseases associated with cell signaling such as cancer, ischemia, inflammation, and glaucoma.
2
Adenosine has served as a good template for the development of A 3 AR ligands. Extensive modification of adenosine resulted in the discovery of Cl-IB-MECA, 1 (K i = 1.0 nM for human A 3 AR) 3 and IB-MECA, 2 (K i = 1.4 nM for human A 3 AR) 4 as potent and selective A 3 AR agonists and these are in clinical trials as anticancer agents 5 ( Fig. 1) . Recently, probing the structure-activity relationship (SAR) of compound 1 on the basis of a bioisosteric rationale indicated that a 4 0 -thionucleoside could serve as an excellent template for the development of A 3 AR agonists, among which compounds 3 and 4 were discovered as more potent A 3 AR agonists (K i = 0.38 and 0.28 nM, respectively) than Cl-IB-MECA 1.
6 Compound 3 also showed potent in vitro as well as in vivo anticancer activity. 7 Because IB-MECA 2 is another representative of A 3 AR agonists, it would be of great interest to synthesize its 4 0 -thio analogue and to compare their biological activities and substituent effects (H vs Cl) at the C2 position. It would be also interesting to study SAR surrounding the 5 0 -uronamide moiety of the 4 0 -thionucleosides. The A 3 AR has displayed a moderate tolerance for sterically bulky substituents at this position, in contrast to the Nmethylamides of the protypical agonists 1 and 2.
6b Herein, we report the synthesis and binding affinity of the series of compound 5 as potent and selective A 3 AR agonists.
Results and discussion
The target nucleoside 5 was synthesized from D-gulonic acid clactone, as shown in Scheme 1.
D-Gulonic acid c-lactone was smoothly converted to the glycosyl donor 6 according to our previously published procedure.
6
Condensation of 6 with 6-chloropurine in the presence of TMSOTf afforded the 6-chloropurine derivative 7 (53%) and its a-anomer (5.4%). 8 The anomeric configuration of 7 was easily confirmed by an NOE effect between 1 0 -H and 4 0 -H. Irradiation on 1 0 -H of compound 6 gave NOE effect on its 4
0 -H, indicating b-anomer, but no NOE effect was observed on the same experiment in the case of its a-anomer. N 6 -(3-iodobenzyl)adenine derivative 9, respectively. For the conversion of 4 0 -hydroxymethyl group into various 5 0 -uronamides, the 2 0 ,3 0 -isopropylidene group was first changed to the 2 0 ,3 0 -di-O-TBS group, because the removal of the 2 0 ,3 0 -isopropylidene group at the final step resulted in the deglycosylation. Treatment of 8 and 9 with 80% acetic acid followed by protection of the resulting diol with the TBS group yielded 10 and 11, respectively. Removal of the benzoyl group in 10 and 11 with sodium methoxide gave the 4 0 -hydroxymethyl derivatives 12 and 13, respectively. 13 (R 2 = 3-iodobenzyl) (82%) Treatment of 12 and 13 with PDC in DMF afforded the carboxylic acid derivatives 14 and 15, respectively (Scheme 2). Coupling of the acids 14 and 15 with various primary amines in the presence of EDC and HOBt yielded various 5 0 -uronamides 5a-w after the removal of the TBS group.
Radioligand binding assay was performed using adherent CHO (Chinese hamster ovary) cells stably transfected with cDNA encoding the human ARs.
9 Bindings at the human ARs were carried out Most of the synthesized compounds showed very high binding affinity at the human A 3 AR with high selectivity in comparison to other subtypes (Table 1) . When compared with the 4 0 -oxonucleoside, IB-MECA (2) (K i = 1.4 nM), the corresponding 4 0 -thionucleoside, thio-IB-MECA (5h) exhibited higher binding affinity at the human A 3 AR (K i = 0.25 nM) as well as higher selectivity over other subtypes, indicating that thio-IB-MECA (5h) has the potential to be developed as a clinical candidate as IB-MECA (2). A similar trend was observed between Cl-IB-MECA (1) (K i = 1.0 nM) and thio-Cl-IB-MECA (3) (K i = 0.38 nM). However, thio-IB-MECA (5h) was found to be less selective (81-vs 508-fold) for the human A 3 AR in comparison to at the human A 1 AR than thio-Cl-IB-MECA (3). This result indicated that substitution of the 2-H atom with more hydrophobic 2-Cl substituent increased the A 3 AR selectivity. 10 It should be noted that thio-IB-MECA (5h) showed the best binding affinity at the human A 3 AR among 4 0 -thionucleosides synthesized so far. This compound also showed very high binding affinity (K i = 1.86 ± 0.36 nM) at the rat A 3 AR. In the N 6 -methyladenine series, the binding affinity at the human A 3 AR of the synthesized 5 0 -uronamides was dependent on the 5 0 -N substitution in the following order: ethyl = cyclopentyl > cyclobutyl > cyclopropylmethyl > methyl > cyclopropyl > 3-iodobenzyl, indicating that alkyl and cycloalkyl derivatives 5a-f showed better binding affinity (K i = 0.97-2.16 nM) than arylalkyl derivative 5g (K i = 15.6 nM). A similar trend was observed in the N 6 -(3-iodobenzyl)adenine series, except that the N 6 -(3-iodobenzyl)adenine derivatives showed slightly better binding affinity at the human A 3 AR and generally were more selective versus the human A 1 AR than the N 6 -methyladenine derivatives.
The most potent and selective compound 5h was a full agonist in an assay of human A 3 adenosine receptor-mediated inhibition of cyclic AMP in transfected CHO cells, as previously observed for compounds 1-4.
In summary, we have established SARs of bioisosteric 4 0 -thio analogues of potent and selective A 3 AR agonist, IB-MECA (2). From this study, thio-IB-MECA (5h) was discovered as being among the most potent A 3 AR agonists and more potent than IB-MECA (2). It was also revealed that small alkyl or cycloalkyl substituents on the 5 0 -uronamide were essential for optimal binding affinity. Bulky substituents on the 5 0 -uronamide, such as cyclohexyl and 2-methylbenzyl, were tolerated, but less potent in A 3 AR binding. We believe that compound 5h has promise to be developed as a clinically useful agent.
Experimental section

1
H NMR spectra (CDCl 3 , CD 3 OD, or DMSO-d 6 ) were recorded on Varian Unity Inova 400 MHz. Chemical shifts were reported in ppm units with TMS as the internal standard.
13
C NMR spectra (CDCl 3 , CD 3 OD, or DMSO-d 6 ) were recorded on Varian Unity Inova 100 MHz. Analytical thin-layer chromatography (TLC) was performed on Merck Silica Gel 60F-254 glass plates. Optical rotations were determined on Jasco III in methanol. UV spectra were recorded on U-3000 made by Histachi in methanol. Elementary analyses were measured on EA1110. The crude products were purified using a Silica Gel 60 (230-400 mesh, Merck). Reagents were purchased from Aldrich Chemical Company. All the anhydrous solvents were distilled over CaH 2 or P 2 O 5 or Na/benzophenone prior to the reaction.
3.1. Benzoic acid (3aS,4R,6R,6aR)-6-(6-chloro-purin-9-yl)-2,2-dimethyl-tetrahydro-thieno [3,4- 
To a suspension of 6-chloropurine (3.36 g, 21. 69 mmol) in a solution of dry CH 3 CN (20 mL) and 1,2-dichloroethane (10 mL) were added Et 3 N (2.19 g, 21.69 mmol) and TMSOTf (9.64 g, 43.38 mmol), and the mixture was stirred at room temperature until the solution was clear. A solution of sulfoxide 6 (3.36 g, 10.85 mmol) in dry 1,2-dichloroethane (10 mL) was added to the resulting solution in one shot at room temperature. An additional amount of Et 3 N (2.19 g, 21.69 mmol) was added to the reaction mixture to initiate the Pummerer reaction. The reaction mixture was stirred under reflux at 80°C for 4 d, during which time the initially formed N-3 isomer was converted to N-9 isomer. The reaction mixture was partitioned between EtOAc and aqueous saturated NaHCO 3 solution, and the organic layer was washed with brine, dried (MgSO 4 ), filtered and evaporated. The residue was purified by flash silica gel column chromatography (hexane/ EtOAc = 5:1) to give 7 (2.57 g, 53%), whose spectral data were identical with those of authentic sample. To a solution of 7 in anhydrous EtOH (20 mL/mmol) were added triethylamine (3.0 equiv) and appropriate amine (1.2 equiv). After being stirred at room temperature for 24 h, the reaction mixture was evaporated. The residue was purified by silica gel column Ki (hA1AR) nM a or % inhibition at 1 lM Ki (hA2AAR) nM a or % inhibition at 1 lM Ki (hA3AR) nM a or % inhibition at 1 lM 
a All AR experiments were performed using adherent CHO cells stably transfected with cDNA encoding the human or rat ARs. Binding was carried out as described in ref. 6 using as radioligand [ chromatography (hexane/ethyl acetate = 1:1) to give the N 6 -substituted nucleosides 8 and 9. , 5.25; N, 15.86; S, 7.26. Found: C, 57.20; H, 5.28; N, 15.75; S, 7 .32. 
General procedure for the preparation of the 4 0 -hydroxymethyl analogues 12 and 13
A solution of per mmol of N 6 -substituted nucleosides (8 and 9) in 80% aqueous AcOH solution (30 mL) was stirred at 70°C for 12 h. The solvent was removed under reduced pressure and the mixture was neutralized with methanolic ammonia. After evaporation, the residue was purified by silica gel column chromatography (CH 2 Cl 2 / MeOH = 10:1) to give diol as a white foam.
To a stirred solution of per mmol of diol in dry pyridine (20 mL) was added a solution of TBDMSOTf (5.0 equiv) dropwise and the reaction mixture was stirred at 50°C for 5 h. The mixture was partitioned between CH 2 Cl 2 and H 2 O and the organic layer was washed with water, aqueous NaHCO 3 solution, water, brine, dried over anhydrous MgSO 4 , and evaporated. The crude disilyl ether was used in the next step without further purification.
To a stirred solution of per mmol of disilyl ether in anhydrous methanol (30 mL) was added sodium methoxide (1.5 equiv) and the mixture was stirred at room temperature for 4 h. After being neutralized with glacial acetic acid, the mixture was evaporated. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1:1) to gave 4 0 -hydroxymethyl analogues 12 and 13, respectively. , 8.24; N, 13.32; S, 6.10. Found: C, 52.40; H, 8.35 ; N, 13.22; S, 6.14. To a stirred solution of 4 0 -hydroxymethyl analogue (1 mmol, 12 and 13) in dry DMF (10 mL) was added pyridinium dichromate (10.0 equiv) and the reaction mixture was stirred at room temperature for 20 h. Water (50 mL) was added to the reaction mixture, and stirred at room temperature for 1 h. The precipitate was filtered and the filter cake was washed with water many times and dried under high vacuum to give the acid (14 and 15) as a brownish solid, which was used in the next step without further purification.
To a solution of 14 and 15 (1 mmol) in CH 2 Cl 2 (20 mL) were added EDC (1.5 equiv), HOBt (1.5 equiv), appropriate amine (1.5 equiv), and DIPEA (3.0 equiv) and the mixture was stirred at room temperature for 15 h. The reaction mixture was evaporated and the residue was purified by a silica gel column chromatography (hexane/ EtOAc = 10:1-5:1) to give the corresponding silyl amide as a white foam. To a stirred solution of silyl amide (1 mmol) in THF (5 mL) was added TBAF (2.5 equiv) and the reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated and the resulting residue was purified by silica gel column chromatography (CH 2 Cl 2 /MeOH = 10:1) to give 5a-w as white solids.
Compound 5a was prepared using methylamineÁHCl: yield 70%; white solid; ½a 
Compound 5b was prepared using ethylamineÁHCl: yield 65%; white solid; ½a 3, 48.9, 50.2, 61.3, 73.2, 74.4, 78.5, 116.3, 140.5, 150.8, 151.5, 152.5, 173.4 
9-(5
Compound 5d was prepared using cyclopropyl methylamineÁHCl: yield 68%; white solid; ½a 
-methyladenine (5f) Compound 5f was prepared using cyclopentylamine: yield 65%; white solid; ½a 4, 24.5, 31.7, 32.5, 38.3, 48.5, 48.6, 65.3, 74.5, 80.4, 129.3, 145.3, 148.5, 153.0, 155.4 3, 50.1, 53.3, 65.4, 78.8, 85.4, 99.4, 125.3, 127.5, 128.4, 130.2, 135.0, 144.2, 145.3, 148.5, 152.3, 156.8, 173.5 3.64; N, 15.97; S, 6.09. Found: C, 41.35; H, 3.66; N, 16.12; S, 6.24. 3.4.8 .
Compound 5h was prepared using methylamineÁHCl: yield 53%; white solid; ½a 5, 60.3, 64.5, 76.0, 78.2, 118.8, 126.4, 133.5, 135.3, 136.0, 140.3, 141.5, 149.9 , 150.4, 153.0, 154.7, 170.3 3.64; N, 15.97; S, 6.09. Found: C, 41.35; H, 3.66; N, 16.12; S, 6.24. 3.4.9 
Compound 5i was prepared using ethylamineÁHCl: yield 66%; white solid; ½a 13 C NMR (CD 3 OD) d 15. 4, 35.3, 44.5, 54.4, 68.0, 79.1, 80.1, 94.5, 120.3, 125.8, 128.5, 130.5, 135.3, 140.4, 142.7, 151.4, 155.5, 172.3, 174.5 , 3.92; N, 15.55; S, 5.93. Found: C, 42.51; H, 3.95; N, 15.73; S, 5.95. 3.4.10. 9 
- (3-iodo-benzyl) .4, 10.5, 24.5, 50.5, 64.3, 66.8, 77.0, 80.4, 116.5, 127.4, 133.5, 135.4, 135.9, 140.3, 141.5, 148.5 , 150.3, 152.9, 153.5, 171.4 4, 35.3, 37.2, 50.5, 54.8, 64.2, 66.5, 78.0, 79.5, 116.4, 126.5, 132.7, 135.3, 135.8, 141.7, 142.3, 148.4, 151.3, 153.0, 154.5, 172 d 20. 5, 22.4, 30.5, 35.4, 36.8, 46.3, 55.6, 64.4, 66.9, 77.5, 79.4, 117.5, 128.4, 133.5, 134. S: C, 46.47; H, 4.58; N, 14.14; S, 5.39. Found: C, 46.55; H, 4.46; N, 14.25; S, - ( 3, 52.4, 54.3, 60.4, 77.4, 78.5, 101.3, 114.3, 115.4, 116.8, 125.7, 125.9, 128.4, 130.5, 135.0, 140.3, 142.1, 145.8, 150.2, 155.31, 158.2, 160.5, 164.8, 173.5 ; FAB-MS m/z 621 (M + +1). Anal. Calcd for C 24 H 22 FIN 6 O 3 S: C, 46.46; H, 3.57; N, 13.55; S, 5.17. Found: C, 46.55; H, 3.46; N, 13.65; S, - ( 4, 52.5, 54.0, 61.3, 78.1, 79.8, 102.3, 114.8, 115.6, 117.2, 125.9, 128.0, 136.3, 138.4, 140.0, 141.2, 142.0, 148.3, 149.5, 150.2, 153.4, 157.2, 158.4, 174 , 45.26; H, 3.48; N, 13.20; S, 5.03. Found: C, 45.46; H, 3.46; N, 13.25; S, 5.26. 3.4.16 . 8, 49.8, 50.3, 52.8, 56.3, 68.4, 78.0, 80.3, 98.6, 102.4, 115.8, 120.3, 125.6, 135.4, 137.6, 139.8, 140.4, 142.5, 146.4, 148.1, 151.3, 154.5, 156.7, 158.4, 173.8 , 4.09; N, 13.63; S, 5.20. Found: C, 48.88; H, 4.14; N, 13.82; S, 5.26. 3.4.17. N 6 -(3-Iodo-benzyl)-9- [5 0 -(3-methyl-benzylaminocarbonyl-4 0 -thio-b-D-ribofuranosyl)]adenine (5q) Compound 5q was prepared using 3-methyl-benzylamine: yield 58%; white solid; ½a 4.09; N, 13.63; S, 5.20. Found: C, 48.85; H, 4.13; N, 13.62; S, 5.15. 3.4.18 8, 50.5, 53.4, 56.5, 67.9, 78.4, 80.5, 98.9, 102.7, 116.3, 120.4, 125.6, 135.5, 136.7, 140.5, 140.9, 142.5, 146.4, 148.2, 151.4, 154.6, 156.8, 158.5, 173.9 , 4.09; N, 13.63; S, 5.20. Found: C, 48.79; H, 4.15; N, 13.55; S, 5.18. 3.4.19 . 4, 52.8, 56.3, 57.8, 68.0, 78.4, 80.9, 98.5, 102.8, 115.8, 120.5, 125.6, 135.8, 137.6, 139.8, 140.5, 142.7, 146.4, 148.1, 151.8, 153.5, 156.9, 158.3, 173.9 3, 52.8, 57.8, 65.2, 67.3, 78.4, 81.0, 98.6, 103.4, 116.4, 120.1, 124.5, 135.7, 137.8, 139.8, 141.3, 142.9, 146.5, 148.3, 152.1, 153.6, 155.4, 158.4, 170 , 4.21; N, 13.00; S, 4.96. Found: C, 48.35; H, 4.24; N, 13.13; S, 5.04. 3.4.21 . 3, 60.4, 73.8, 89.1, 98.4, 121.2, 122.4, 122.5, 124.1, 124.8, 126.3, 127.0, 127.8, 128.1, 129.2, 132.4, 133.5, 135.4, 136.0, 144.8, 145.5, 147.8, 152.0, 154.4, 156.8, 174.4 , 3.86; N, 12.88; S, 4.91. Found: C, 51.68; H, 3.92; N, 12.92; S, 4.90. 3.4.22 3, 44.5, 45.3, 56.0, 60.3, 74.2, 79.8, 97.3, 123.1, 123.4, 124.5, 125.3, 126.4, 126.8, 127.1, 128.4, 129.4, 136.2, 137.1, 144.3, 145 4.09; N, 13.63; S, 5.20. Found: C, 48.79; H, 4.15; N, 13.55; S, 0 -thio-b-Dribofuranosyl)]-N 6 -(3-iodobenzyl)adenine (5w)
Compound 5w was prepared using 3,3-diphenylpropylamine: yield 72%; white solid; ½a 13 C NMR (CD 3 OD) d 34. 5, 35.3, 40.6, 45.5, 60.1, 73.4, 79.1, 80.4, 97.1, 112.3, 120.5, 126.0, 128.4, 129.3, 129.5, 129.7, 129.9, 132.7, 135.3, 141.5, 143.0, 144.3, 147.8, 152.4, 155.7, 174.8 S: C, 54.39; H, 4.42; N, 11.89; S, 4.54. Found: C, 54.48; H, 4.45; N, 11.75; S, 4.64. 
